467P - The prognostic value of Serum Cripto-1 in patients with non-small cell lung

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Rasha Haggag
Citation Annals of Oncology (2016) 27 (suppl_9): ix139-ix156. 10.1093/annonc/mdw594
Authors R.M. Haggag1, S. El-Shorbagy1, H.F. Ebian2, H.A. Labib3
  • 1Medical Oncology, Zagazig University Faculty of Medicine, 44519 - Zagazig/EG
  • 2Clinical Pathology, Zagazig University Faculty of Medicine, 44519 - Zagazig/EG
  • 3Clinical Pathology, Zagazig University Faculty of Medicine, 445109 - Zagazig/EG

Abstract

Background

Cripto-1 (CR-1) is a member of the epidermal growth factor-cripto FRL1 cryptic (EGF-CFC) family. It plays an important role in tumorigenesis by promoting cell proliferation, survival, migration, invasion and tumor angiogenesis. CR-1 is over-expressed in lung cancer tissues, and the levels of CR-1 expression are associated with the prognosis.

Methods

To explore the diagnostic and prognostic value of serum CR-1 levels in patients with NSCLC, Serum CR-1, VEGF, and CRP concentrations were measured using enzyme-linked immunosorbent assay.

Results

Our study enrolled 91 non-small cell lung cancer (NSCLC) lung cancer patients (19 females and 75 males), and 31as control subjects (9 females and 22 males) from December 2013 through November 2015. Sex- and age-matched healthy volunteers were enrolled in the same period (P = 0.2 and 0.08, respectively). Patients with lung cancer had higher serum CR-1 levels than the control group (3.7± 1.03 ng/mL vs. 1.08 ± 0.38 ng/mL, p 

Conclusions

Measurement of serum CR-1 and VEGF levels can be considered as useful promising diagnostic and prognostic markers for NSCLC patients.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.